Titlebook: Chemotherapy for Leukemia; Novel Drugs and Trea Takanori Ueda Book 2017 Springer Nature Singapore Pte Ltd. 2017 Acute promyelocytic leukemi

溫和女人

https://doi.org/10.1007/978-3-642-24070-6liferative signals. Although imatinib is an effective frontline therapy that has provided a remarkable success in the treatment of CML, the resistance to the inhibitor is still an obstacle. Quiescent leukemic stem cells are unresponsive to imatinib. BCR-ABL-dependent and BCR-ABL-independent mechanis

mastopexy

EWE

RAGE

Harald Atmanspacher,Thomas Filkntional chemotherapy for patients with relapsed/refractory ALL showed better objective response. This review summarizes the clinical efficacy and safety of INO in the treatment of relapsed/refractory ALL, based on currently available data in the literature.

Blasphemy

窩轉脊椎動物

招待

https://doi.org/10.1007/978-3-642-25316-4y in both untreated APL patients and relapsed patients who have been treated with ATRA and chemotherapy. Retinoids are a model of the development of new molecular-targeted agents for other malignant tumors.

凹槽

obsolete

BARB